KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Gross Margin (2016 - 2023)

TherapeuticsMD (TXMD) has disclosed Gross Margin for 13 consecutive years, with 100.0% as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Gross Margin changed 0.0% year-over-year to 100.0%, compared with a TTM value of 92.47% through Dec 2023, up 2852.0%, and an annual FY2023 reading of 100.0%, up 200.0% over the prior year.
  • Gross Margin was 100.0% for Q4 2023 at TherapeuticsMD, up from 100.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 2082.45% in Q1 2022 and bottomed at 10817.51% in Q3 2022.
  • Average Gross Margin over 5 years is 392.07%, with a median of 80.67% recorded in 2021.
  • The sharpest move saw Gross Margin plummeted -1089672bps in 2022, then surged 1071751bps in 2023.
  • Year by year, Gross Margin stood at 118.39% in 2019, then crashed by -36bps to 75.28% in 2020, then grew by 7bps to 80.67% in 2021, then grew by 24bps to 100.0% in 2022, then changed by 0bps to 100.0% in 2023.
  • Business Quant data shows Gross Margin for TXMD at 100.0% in Q4 2023, 100.0% in Q3 2023, and 100.0% in Q2 2023.